Stockscreener 앱 받기
170.69
8.83%
-16.53
시장 영업 전:
169.03
-1.66
-0.97%
전일 마감가:
$187.22
열려 있는:
$188
하루 거래량:
3.39M
Relative Volume:
1.60
시가총액:
$22.91B
수익:
$1.08B
순이익/손실:
$-433.19M
주가수익비율:
-50.20
EPS:
-3.4004
순현금흐름:
$-225.09M
1주 성능:
-3.96%
1개월 성능:
+5.75%
6개월 성능:
+90.37%
1년 성능:
+169.31%
1일 변동 폭
$170.05
$191.05
1주일 범위
$170.05
$191.05
52주 변동 폭
$61.00
$191.05
가든트헬스 Stock (GH) Company Profile
명칭
Guardant Health Inc
전화
855-698-8887
주소
3100 HANOVER STREET, PALO ALTO
Compare GH vs TMO, DHR, NTRA, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
170.69 | 23.79B | 1.08B | -433.19M | -225.09M | -3.4004 |
TMO
Thermo Fisher Scientific Inc
|
656.58 | 241.26B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
215.61 | 150.48B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
400.65 | 59.47B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
169.33 | 48.71B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
436.43 | 42.59B | 3.77B | 449.25M | 240.68M | 7.8556 |
가든트헬스 Stock (GH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-20 | 재확인 | Canaccord Genuity | Buy |
| 2026-02-17 | 개시 | Robert W. Baird | Outperform |
| 2026-01-05 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-12-02 | 재개 | Morgan Stanley | Overweight |
| 2025-09-25 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-09-22 | 재개 | Wells Fargo | Overweight |
| 2025-04-10 | 개시 | Mizuho | Outperform |
| 2025-01-23 | 개시 | Barclays | Overweight |
| 2024-06-28 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-04-24 | 재개 | Craig Hallum | Buy |
| 2023-12-14 | 개시 | Guggenheim | Neutral |
| 2023-12-13 | 개시 | Wolfe Research | Peer Perform |
| 2023-11-13 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-09-28 | 개시 | Bernstein | Outperform |
| 2023-09-27 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-05-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-05-05 | 개시 | UBS | Buy |
| 2023-03-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-11-01 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-10-19 | 개시 | Craig Hallum | Buy |
| 2022-10-06 | 개시 | Stephens | Overweight |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-06-03 | 개시 | Piper Sandler | Overweight |
| 2022-04-28 | 재개 | BTIG Research | Buy |
| 2022-02-24 | 재확인 | Canaccord Genuity | Buy |
| 2022-02-24 | 재확인 | Citigroup | Buy |
| 2022-02-24 | 재확인 | Cowen | Outperform |
| 2022-02-24 | 재확인 | Morgan Stanley | Overweight |
| 2022-02-24 | 재확인 | SVB Leerink | Outperform |
| 2022-02-24 | 재확인 | Stifel | Buy |
| 2022-02-24 | 재확인 | Wells Fargo | Overweight |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-06-15 | 개시 | Raymond James | Mkt Perform |
| 2021-06-03 | 개시 | Goldman | Buy |
| 2021-05-25 | 개시 | Wells Fargo | Overweight |
| 2021-01-11 | 개시 | Stifel | Buy |
| 2020-09-09 | 개시 | Morgan Stanley | Overweight |
| 2020-06-12 | 개시 | BTIG Research | Buy |
| 2020-02-21 | 개시 | Guggenheim | Buy |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-08-07 | 재확인 | Canaccord Genuity | Buy |
| 2019-04-16 | 개시 | Canaccord Genuity | Buy |
| 2019-04-10 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-02-28 | 재확인 | BofA/Merrill | Neutral |
| 2018-10-29 | 개시 | BofA/Merrill | Neutral |
| 2018-10-29 | 개시 | JP Morgan | Overweight |
| 2018-10-29 | 개시 | William Blair | Outperform |
모두보기
가든트헬스 주식(GH)의 최신 뉴스
Natera CEO Steve Chapman: Treatment on Molecular Recurrence Will Reshape Oncology in 5 Years - finance.biggo.com
Guardant Health, Inc. (GH) stock price, news, quote and history - uk.finance.yahoo.com
Asset turnover of Guardant Health, Inc. – HAN:5GH - TradingView
ETFs Investing in Guardant Health, Inc. Stocks - TradingView
Could Guardant Health (NASDAQ:GH) Reset Its Market Story? - Kalkine Media
Guardant Health, Inc. (GH) Stock Price, News, Quote & History - Yahoo! Finance Canada
This test screens for 50 cancers — but whether Medicare and other health insurers will cover it hinges on FDA approval - marketwatch.com
Form 4 Guardant Health Inc For: 22 September By Investing.com - Investing.com Canada
Guardant Health (GH) director adds 264 shares from RSU vesting - Stock Titan
Guardant Health Inc (GH) Shares Fall 3.1% -- What GF Score of 65 Tells Investors - gurufocus.com
Tempus AI Fails to Trim Guardant Lawsuit Over Diagnostic Tests - news.bloomberglaw.com
Goldman Sachs Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $225 - moomoo.com
Guardant Health, Inc. (GH) Stock Analysis: A Strong Buy With 9% Upside Potential - DirectorsTalk Interviews
Guardant Health’s Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening - The National Law Review
Guardant Health Director Steve E. Krognes Sells 6,674 Shares Between $174.46 and $177.48 - Kalkine Media
Barclays Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $200 - Moomoo
Guardant Health (GH) Lands First FDA Cleared Breast Cancer Liquid Biopsy Role - Yahoo Finance
Director Steve Krognes Sells 6,674 Shares of Guardant Health Inc (GH) - GuruFocus
Guardant Health on Track for Record High Close -- Data Talk - Bitget
Cathie Wood’s ARK increases stake in Guardant Health stock - Investing.com
Guardant Health (GH) director plans new stock sale - Stock Titan
Guardant Health (NASDAQ: GH) director may sell $144K in equity-comp stock - stocktitan.net
Guardant Health (NASDAQ: GH) director moves to sell 6,674 shares - Stock Titan
Testing & Diagnostics Services Stocks Q2 Results: Benchmarking Guardant Health (NASDAQ:GH) - Yahoo Finance
Cathie Wood’s ARK buys Guardant Health stock, sells Iridium - Investing.com
Officer at Guardant Health (NASDAQ: GH) plans sale of 7,738 shares under Rule 144 - Stock Titan
Guardant Health stock hits 52-week high at 176.68 USD - Investing.com
Guardant Health (GH) Insider Sale: Chief Information Officer Kum - GuruFocus
Guardant Health CIO Kumud Kalia sells $632k in stock - Investing.com
Is Guardant Health Inc (GH) Overvalued After 6.6% Rally? GF Valu - GuruFocus
Guardant Health rises as investors weigh recent FDA approval, coverage expansion, and supportive analyst views - Quiver Quantitative
Guardant Health’s Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening - FinancialContent
Guardant Health, Inc. (GH) Stock Analysis: 24% Upside Potential Amid Strong Buy Ratings - DirectorsTalk Interviews
Guardant Health Inc Share PriceGH, RNS News, Articles, Quotes, & Charts - Proactive financial news
Guardant Health (NASDAQ: GH) officer moves to sell more stock - stocktitan.net
(GH) Volatility Zones as Tactical Triggers - Stock Traders Daily
Bernstein reiterates Guardant Health stock rating on margin outlook - Investing.com
Bernstein reiterates Guardant Health stock rating on margin outlook By Investing.com - Investing.com Canada
Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer - BioSpace
GH Maintained by UBS -- Price Target Raised to $225 - GuruFocus
Guardant Health and Collaborators Present 20 Abstracts Showcasing Advances in Liquid Biopsy Tests and Methylation-Based Tumor Classification for Lung Cancer At 2026 World Conference on Lung Cancer - marketscreener.com
UBS Adjusts Guardant Health Price Target to $225 From $175, Maintains Buy Rating - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
GH Initiates Coverage On Guardant Health -- Buy Rating by Rothsc - GuruFocus
Business Insider Names Guardant Health One of America's Most Innovative Businesses - Business Wire
What Makes Guardant Health (GH) a Compelling Bet? - Yahoo Finance
Rothschild Redburn initiates Guardant Health stock with buy rating By Investing.com - Investing.com Canada
Rothschild Redburn initiates Guardant Health stock with buy rating - investing.com
Rothschild & Co Redburn Initiates Guardant Health at Buy - Yahoo Finance
AstraZeneca Secures FDA Nod for New Breast Cancer Therapy Etcamah - Zacks Investment Research
Guardant Health, Inc. (GH) Stock Analysis: Unveiling a 20% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
가든트헬스 (GH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
가든트헬스 주식 (GH) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Monroe Terilyn J. | Chief People Officer |
Oct 01 '26 |
Option Exercise |
0.00 |
4,019 |
0 |
26,998 |
| Kalia Kumud | Chief Information Officer |
Oct 01 '26 |
Option Exercise |
0.00 |
6,046 |
0 |
45,840 |
| Freeman Chris | Chief Commercial Officer |
Oct 01 '26 |
Option Exercise |
0.00 |
7,416 |
0 |
72,790 |
| Chudova Darya | Chief Technology Officer |
Oct 01 '26 |
Option Exercise |
0.00 |
8,033 |
0 |
78,668 |
| Bell Michael Brian | Chief Financial Officer |
Oct 01 '26 |
Option Exercise |
0.00 |
7,280 |
0 |
59,096 |
| Talasaz AmirAli | Co-Chief Executive Officer |
Sep 30 '26 |
Option Exercise |
0.00 |
2,817 |
0 |
1,827,168 |
| Talasaz AmirAli | Co-Chief Executive Officer |
Oct 01 '26 |
Option Exercise |
0.00 |
33,713 |
0 |
1,859,453 |
| Eltoukhy Helmy | Co-Chief Executive Officer |
Sep 30 '26 |
Option Exercise |
0.00 |
2,817 |
0 |
1,943,751 |
| Eltoukhy Helmy | Co-Chief Executive Officer |
Oct 01 '26 |
Option Exercise |
0.00 |
33,713 |
0 |
1,976,036 |
| MIGNONE ROBERTO | Director |
Sep 21 '26 |
Option Exercise |
0.00 |
264 |
0 |
10,274 |
0.99%
0.56%
자본화:
|
볼륨(24시간):